Fosun Pharma Subsidiary Henlius Obtains Global Exclusive License for Two T-Cell Engagers from the T-MATE Platform

en.Wedoany.com Reported - On September 23, Fosun Pharma announced that its controlled subsidiary Shanghai Henlius Biotech, Inc. has entered into a collaboration and license agreement with Amberstone Biosciences. Under the agreement, Henlius obtains a global exclusive license to develop two T-cell engager products targeting agreed targets based on the Amberstone T-MATE™ technology platform. The license covers all fields of human use and includes the rights to research, develop, manufacture, and commercialize the relevant products.

Under the terms of the agreement, Henlius will pay Amberstone an upfront payment, research and development costs, and development and regulatory milestone payments, totaling no more than US$236 million; if the products subsequently achieve agreed sales targets, Henlius will also pay sales milestone payments of no more than US$652 million. In addition, after the collaboration products are commercialized, Amberstone will also receive sales royalties as agreed under the agreement.

This collaboration involves the T-MATE™ technology platform, which is used to develop T-cell engager drugs. T-cell engagers direct T cells to carry out immune killing of target cells by simultaneously recognizing tumor-associated targets and molecules on the surface of T cells. The specific targets, current development stages, clinical advancement timelines, and product codes of the two licensed candidate products have not been disclosed in the announcement.

According to the agreement, Henlius will be responsible for the subsequent global research and development, registration, manufacturing, and commercialization of the two licensed products, while Amberstone will continue to provide technical support and collaboration related to the T-MATE™ platform. Payment arrangements will be executed in stages based on research and development, clinical, regulatory, and commercialization progress, and the actual payment amounts will depend on whether subsequent milestones are achieved.

The total maximum transaction amount for this deal reaches US$888 million, of which development and regulatory-related payments amount to no more than US$236 million, and sales milestones amount to no more than US$652 million. Subsequent progress of the project will depend on candidate product screening, preclinical research, clinical trials, regulatory approvals, and commercialization advancement.